Show simple item record

dc.contributor.authorFerradini, L
dc.contributor.authorLaureillard, D
dc.contributor.authorPrak, N
dc.contributor.authorNgeth, C
dc.contributor.authorFernandez, M
dc.contributor.authorPinoges, L
dc.contributor.authorPuertas, G
dc.contributor.authorTaburet, A
dc.contributor.authorLy, N
dc.contributor.authorRouzioux, C
dc.contributor.authorBalkan, S
dc.contributor.authorQuillet, C
dc.contributor.authorDelfraissy, J F
dc.date.accessioned2008-03-06T14:23:30Z
dc.date.available2008-03-06T14:23:30Z
dc.date.issued2007-11-12
dc.identifier.citationPositive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. 2007, 21 (17):2293-301 AIDS
dc.identifier.issn0269-9370
dc.identifier.pmid18090277
dc.identifier.doi10.1097/QAD.0b013e32828cc8b7
dc.identifier.urihttp://hdl.handle.net/10144/19977
dc.description.abstractOBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings.
dc.language.isoen
dc.rightsPublished by Wolters Kluwer Lippincott Williams & Wilkins - Archived on this site by kind permission Wolters Kluweren_GB
dc.titlePositive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia.
dc.contributor.departmentEpicentre, Paris, France. msffr.comed@online.com.kh
dc.identifier.journalAIDS
refterms.dateFOA2019-03-04T09:33:43Z
html.description.abstractOBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings.


Files in this item

Thumbnail
Name:
Positive outcomes of HAART- AIDS ...
Size:
139.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record